RecruitingNCT01834001

Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy

Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided Biopsies


Sponsor

National Cancer Institute (NCI)

Enrollment

300 participants

Start Date

Nov 13, 2013

Study Type

OBSERVATIONAL

Conditions

Summary

Background: \- Radiation is a common treatment for prostate cancer. It helps damage tumor cells and causes them to die. Radiation can be effective, but some tumors may be harder to treat with radiation or even with surgery. This happens to a small number of men who have either radiation or surgery for prostate cancer. Most men who have these hard-to-treat tumors do not know if the tumor has recurred only in the prostate or has spread to another area. Also, men whose prostate cancer has recurred only after radiation may have different treatment options. This study will use improved imaging studies to better understand why some men do not respond as well to initial radiation treatments. Objectives: \- To use detailed imaging studies to look at the results of local radiation therapy for prostate cancer. Eligibility: * Men at least 18 years of age who are scheduled to have radiation for prostate cancer. * Men at least 18 years of age whose prostate cancer has returned after earlier treatments. Design: * All participants will have a medical history and physical exam. Blood and urine samples will be collected. Imaging studies will be used to evaluate the cancer at the start of the study. * All participants will have an initial full magnetic resonance imaging (MRI) scan of the prostate. Tumor and healthy tissue samples will be collected. * Those whose cancer has recurred after treatment will discuss possible treatment options with the study doctors. * Participants who are scheduled to have radiation will have radiation therapy. This will be given according to the current standard of treatment. * After radiation, participants will have regular follow-up tests and imaging studies. They will have another full MRI scan 6 months after the end of radiation treatment.


Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study uses advanced imaging — including special MRI scans — to monitor how prostate cancer responds to radiation treatment, and to detect early signs of recurrence (cancer coming back). **You may be eligible if...** - You are a man 18 or older with confirmed prostate cancer (intermediate or high risk) - You have not yet received any local treatment (surgery, radiation, or freezing) or hormone therapy for your prostate cancer - You are planning to have radiation as your main treatment, OR you have had radiation in the past and there are signs your cancer may have returned **You may NOT be eligible if...** - You have a pacemaker, metal implants, or other MRI-incompatible devices - Your cancer has clearly spread to distant parts of the body - You have a bleeding disorder or are on blood-thinning medications - You have an active urinary tract infection - You have kidney disease severe enough to prevent contrast MRI dye - You are HIV positive or have active Hepatitis B or C Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

National Institutes of Health Clinical Center

Bethesda, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT01834001


Related Trials